NCT02131597已完成2 期
Phase 2 Study of SGI-110 in Patients With Higher Risk MDS
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Number of Participants With a Complete Response (CR)
研究概览
简要总结
This phase II trial studies how well guadecitabine works in treating patients with myelodysplastic syndromes that are at higher risk for becoming acute myeloid leukemia. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the complete response (CR) rate with SGI-110 (guadecitabine) in patients with higher risk myelodysplastic syndrome (MDS).
SECONDARY OBJECTIVES:
I. Overall response rate, survival, transformation to acute myeloid leukemia (AML), transfusion independence.
II. Safety and toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with higher risk MDS (International Prognostic Scoring System [IPSS] int-2 or high; or >= 10% blasts as defined by World Health Organization [WHO])
- •No prior intensive chemotherapy or high-dose cytarabine (>= 1 g/m^2)
- •Prior biologic therapies (=< 1 cycle of prior decitabine or azacitidine), targeted therapies, or single agent chemotherapy is allowed
- •Off chemotherapy for 2 weeks prior to entering this study with no toxic effects of that therapy, unless there is evidence of rapidly progressive disease
- •Hydroxyurea is permitted for control of counts prior to treatment
- •Hematopoietic growth factors are allowed
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- •Serum creatinine =< 1.5 mg/dL
- •Serum bilirubin =< 1.5 x upper limit of normal (ULN)
- •Aspartate transaminase (AST) or alanine transaminase (ALT) =< 2.5 x ULN
- •Alkaline phosphatase =< 2.5 x ULN
- •Provide signed written informed consent
- •Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
- •Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to entering this study
- •Women who are able to become pregnant and men who can father a child must use birth control while on study and for at least 8 weeks after your last dose of study drug(s); acceptable birth control includes a condom or a diaphragm with spermicidal jelly; and birth control methods that are taken by mouth, injected, or implanted; if you are already using birth control, you must check with the study staff to make sure that it is considered one of the acceptable forms to use in this study
排除标准
- •Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol
- •Use of investigational agents within 30 days or any anticancer therapy within 2 weeks prior to entering this study with the exception of hydroxyurea; the patient must have recovered from all acute toxicities from any previous therapy
- •Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment
- •Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- •Pregnant or lactating patients
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
- •Any concurrent malignancy
- •Exceptions
- •Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed
- •Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
研究组 & 干预措施
Treatment (guadecitabine)
Experimental
Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
干预措施: Guadecitabine (Drug)
结局指标
主要结局
Number of Participants With a Complete Response (CR)
时间窗: At cycle 3 and cycle 6, cycles are up every 4 to 8 weeks. Up to 9 years, 8 months and 15 days.
Complete Response is Normalization of the peripheral blood and bone marrow with \</= 5% bone marrow blasts, a peripheral blood granulocyte count \>/= 1.0 x 10\^9/L, and a platelet count \>/= 100 x 10\^9/L. Hemoglobin \>/= 11 g/dL at any point while on treatment after the first cycle of therapy.
次要结局
- Overall Survival(Up to 9 years, 8 months and 15 days)
- Time to Acute Myeloid Leukemia (AML) Transformation(Up to 9 years, 8 months and 15 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeAcute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT02684162M.D. Anderson Cancer Center55
Unknown
2 期
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell TransplantationMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT03454984Groupe Francophone des Myelodysplasies40
撤回
1 期
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerColorectal AdenocarcinomaCpG Island Methylator PhenotypeMetastatic Microsatellite Stable Colorectal CarcinomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8NCT03576963University of Southern California
已完成
2 期
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT02096055M.D. Anderson Cancer Center44
进行中（未招募）
1 期
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerExtrahepatic Bile Duct Adenocarcinoma, Biliary TypeGallbladder Adenocarcinoma, Biliary TypeMetastatic Pancreatic AdenocarcinomaRecurrent CholangiocarcinomaRecurrent Gallbladder CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Intrahepatic CholangiocarcinomaRecurrent Pancreatic CarcinomaStage III Gallbladder Cancer AJCC V7Stage III Hepatocellular Carcinoma AJCC v7Stage III Intrahepatic Cholangiocarcinoma AJCC v7Stage III Pancreatic Cancer AJCC v6 and v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Gallbladder Cancer AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Gallbladder Cancer AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7Stage IVB Gallbladder Cancer AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7Unresectable Gallbladder CarcinomaUnresectable Pancreatic CarcinomaNCT03257761University of Southern California55